Of therapeutic importance, Runx3 overexpression in LCMV-specific CD8 T cells promoted T cell access to viral antigen-expressing B16 tumors, enforced the acquisition of a TRM phenotype in tumors, and enhanced T cell anti-tumor activity (54). This evidence concerns the gene CD8A and neoplasm.